Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development.J Infect Dis. 2020 06 29; 222(2):180-182.JI
Links
MeSH
Pub Type(s)
Journal Article
Language
eng
PubMed ID
32365191
Citation
Graepel, Kevin W., et al. "Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development." The Journal of Infectious Diseases, vol. 222, no. 2, 2020, pp. 180-182.
Graepel KW, Kochhar S, Clayton EW, et al. Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development. J Infect Dis. 2020;222(2):180-182.
Graepel, K. W., Kochhar, S., Clayton, E. W., & Edwards, K. E. (2020). Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development. The Journal of Infectious Diseases, 222(2), 180-182. https://doi.org/10.1093/infdis/jiaa234
Graepel KW, et al. Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development. J Infect Dis. 2020 06 29;222(2):180-182. PubMed PMID: 32365191.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development.
AU - Graepel,Kevin W,
AU - Kochhar,Sonali,
AU - Clayton,Ellen W,
AU - Edwards,Kathryn E,
PY - 2020/04/26/received
PY - 2020/04/30/accepted
PY - 2020/5/5/pubmed
PY - 2020/7/8/medline
PY - 2020/5/5/entrez
SP - 180
EP - 182
JF - The Journal of infectious diseases
JO - J Infect Dis
VL - 222
IS - 2
SN - 1537-6613
UR - https://www.unboundmedicine.com/medline/citation/32365191/Balancing_Expediency_and_Scientific_Rigor_in_Severe_Acute_Respiratory_Syndrome_Coronavirus_2_Vaccine_Development_
DB - PRIME
DP - Unbound Medicine
ER -